3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma.

      Nature reviews. Drug discovery

      Administration, Ophthalmic, Animals, Drug Delivery Systems, methods, trends, Drug Discovery, Genetic Therapy, Glaucoma, drug therapy, genetics, metabolism, Humans, Ophthalmic Solutions, administration & dosage, Retinal Diseases

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Blindness affects 60 million people worldwide. The leading causes of irreversible blindness include age-related macular degeneration, retinal vascular diseases and glaucoma. The unique features of the eye provide both benefits and challenges for drug discovery and delivery. During the past decade, the landscape for ocular drug therapy has substantially changed and our knowledge of the pathogenesis of ophthalmic diseases has grown considerably. Anti-angiogenic drugs have emerged as the most effective form of therapy for age-related macular degeneration and retinal vascular diseases. Lowering intraocular pressure is still the mainstay for glaucoma treatment but neuroprotective drugs represent a promising next-generation therapy. This Review discusses the current state of ocular drug therapy and highlights future therapeutic opportunities.

          Related collections

          Author and article information

          Journal
          22699774
          10.1038/nrd3745

          Comments

          Comment on this article